Patents by Inventor Costas A. Lyssiotis

Costas A. Lyssiotis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 11246873
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: February 15, 2022
    Assignee: The Scripps Research Institute
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
    Publication number: 20200390780
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Application
    Filed: April 8, 2020
    Publication date: December 17, 2020
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
    Patent number: 10837015
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 17, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 10660899
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: May 26, 2020
    Assignees: The Scripps Research Institute, Novartis AG
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 10493080
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: December 3, 2019
    Assignees: The Scripps Research Institute, Novartis AG
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Small molecule inhibitor of 3-phosphoglycerate dehydrogenase and uses thereof
    Patent number: 10494365
    Abstract: Embodiments of the present invention are directed to small molecule inhibitors of PHGDH. Other embodiments of the present invention relate to methods of treating cancers using the small molecule inhibitors of PHGDH disclosed herein. Still other embodiments of the present invention relate to methods for using the small molecule inhibitors of PHGDH to study serine metabolism.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: December 3, 2019
    Assignees: Cornell University, The Scripps Research Institute
    Inventors: Lewis C. Cantley, Edouard Mullarky, Costas Lyssiotis, Luke L. Lairson, Natasha Lucki
  • TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20190136238
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • SMALL MOLECULE INHIBITOR OF 3-PHOSPHOGLYCERATE DEHYDROGENASE AND USES THEREOF
    Publication number: 20190010144
    Abstract: Embodiments of the present invention are directed to small molecule inhibitors of PHGDH. Other embodiments of the present invention relate to methods of treating cancers using the small molecule inhibitors of PHGDH disclosed herein. Still other embodiments of the present invention relate to methods for using the small molecule inhibitors of PHGDH to study serine metabolism.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 10, 2019
    Inventors: Lewis C. Cantley, Edouard Mullarky, Costas Lyssiotis, Luke L. Lairson, Natasha Lucki
  • Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
    Patent number: 10138479
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: November 27, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Methods for diagnosing and treating oncogenic kras-associated cancer
    Patent number: 9745631
    Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: August 29, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Ronald A. DePinho, Lewis Cantley, Alec C. Kimmelman, Haoqiang Ying, Costas A. Lyssiotis
  • DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
    Publication number: 20170136029
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
    Patent number: 9592288
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: March 14, 2017
    Assignees: The Scripps Research Institute, IRM LLC
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
    Publication number: 20160166687
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 16, 2016
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • COLORECTAL CANCER CLASSIFICATION WITH DIFFERENTIAL PROGNOSIS AND PERSONALIZED THERAPEUTIC RESPONSES
    Publication number: 20150354009
    Abstract: The present invention relates to gene sets, the expression levels of which are useful for classifying colorectal tumors and predicting disease-free prognosis and response of patients to specific therapies that are either novel or currently available in the clinics for colorectal cancer patients.
    Type: Application
    Filed: November 26, 2013
    Publication date: December 10, 2015
    Inventors: Anguraj SADANANDAM, Costas LYSSIOTIS, Douglas HANAHAN, Joe GRAY
  • METHODS FOR DIAGNOSING AND TREATING ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20150126580
    Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 7, 2015
    Inventors: Ronald A. DePinho, Lewis Cantley, Alec C. Kimmelman, Haoqiang Ying, Costas A. Lyssiotis
  • TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20150110773
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 23, 2015
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
    Publication number: 20140038949
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Application
    Filed: February 17, 2012
    Publication date: February 6, 2014
    Applicants: IRM LLC, The Scripps Research Institute
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis